As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.
September 20, 2018
· 1 min read